Lv7
3270 积分 2020-06-30 加入
Targeting APRIL in the treatment of glomerular diseases
4天前
已完结
Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report
4天前
已完结
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
8天前
已完结
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study
8天前
已完结
Trends in the drug target landscape for autoimmune diseases
17天前
已完结
The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis
24天前
已完结
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
24天前
已完结
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis
24天前
已完结
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension
24天前
已完结
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions
24天前
已完结
皖公网安备34019202002308
